Geisinger, Boehringer Ingelheim collaborate on a risk-prediction model for type 2 diabetes
Geisinger | September 27, 2017
Geisinger and pharmaceutical partner Boehringer Ingelheim will collaborate with pharmaceutical giant Eli Lilly to develop a risk-prediction model for three critical health outcomes commonly associated with type 2 diabetes: cardiovascular death, kidney failure and hospitalization for heart failure.